Literature DB >> 24388313

A novel claudin-16 mutation, severe bone disease, and nephrocalcinosis.

Luxme Nadarajah1, Maryam Khosravi2, Simona Dumitriu2, Enriko Klootwijk2, Robert Kleta2, Muhammad M Yaqoob1, Stephen B Walsh3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24388313     DOI: 10.1016/S0140-6736(13)62673-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Clinical utility gene card for: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis with/without severe ocular involvement.

Authors:  Félix Claverie-Martín; Rosa Vargas-Poussou; Dominik Müller; Víctor García-Nieto
Journal:  Eur J Hum Genet       Date:  2014-09-03       Impact factor: 4.246

2.  Identification of the first large deletion in the CLDN16 gene in a patient with FHHNC and late-onset of chronic kidney disease: case report.

Authors:  Paulo Marcio Yamaguti; Pollyanna Almeida Costa dos Santos; Bruno Sakamoto Leal; Viviane Brandão Bandeira de Mello Santana; Juliana Forte Mazzeu; Ana Carolina Acevedo; Francisco de Assis Rocha Neves
Journal:  BMC Nephrol       Date:  2015-07-02       Impact factor: 2.388

Review 3.  Claudins in Renal Physiology and Pathology.

Authors:  Caroline Prot-Bertoye; Pascal Houillier
Journal:  Genes (Basel)       Date:  2020-03-10       Impact factor: 4.096

4.  Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics.

Authors:  Felix Claverie-Martin
Journal:  Clin Kidney J       Date:  2015-09-01

5.  Familial hypomagnesaemia, Hypercalciuria and Nephrocalcinosis associated with a novel mutation of the highly conserved leucine residue 116 of Claudin 16 in a Chinese patient with a delayed diagnosis: a case report.

Authors:  Jingru Lu; Xiangzhong Zhao; Alessandro Paiardini; Yanhua Lang; Irene Bottillo; Leping Shao
Journal:  BMC Nephrol       Date:  2018-07-13       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.